DRUGS · SERVICE DETAILS

Drug Master File (DMF) Services

We support API, pharmaceutical packaging and excipient companies with technical preparation, electronic filing, Letters of Authorization (LOAs) and lifecycle maintenance. Confirm file type, available documents and customer references before agreeing on deliverables and fees.

A DMF holds technical information that authorized parties can reference. FDA does not approve or disapprove a DMF on its own. A file number, acknowledgement and technical review outcome each have a distinct meaning.

SERVICE OVERVIEW

From initial preparation through customer references and maintenance

For an initial DMF, we assess the type and documentation gaps, prepare agreed content using your actual manufacturing, quality and study data, and coordinate the applicable electronic submission. For an existing DMF, we can help with LOAs, amendments, annual reports, FDA responses and handover. Deliverables may include a gap list, agreed sections, electronic files, acknowledgements and maintenance records.

WHO MAY NEED IT

Who should consider this service?

API manufacturers, packaging and excipient suppliers, DMF holders and their authorized teams preparing or maintaining a DMF. We generally start with Types II, III and IV. Type V and specialized submissions depend on the file’s purpose.

Define DMF services by project stage

  • No DMF yet:Provide the material name and use, manufacturing sites, and an inventory of process and quality documents. Check whether Type II, III or IV applies, then confirm gaps, sections and eCTD submission scope. Ask about initial preparation and submission。
  • Existing DMF with a customer planning to reference it:Provide the DMF number, holder, prior submissions and the customer’s intended reference scope. Identify material and versions eligible for authorization, then confirm LOA and electronic file support. Ask about an LOA。
  • Existing DMF needing maintenance:Provide the most recent submission date, changes and prior acknowledgements. Process, specification or site changes may require technical amendments. Confirm annual reporting and FDA responses separately. Ask about annual maintenance and amendments。

Start with an inventory. Agree on how to exchange sensitive technical documents. Read the Guide to DMF types, LOAs and electronic submissions, or share your project stage to confirm the service scope. For references and holder maintenance, see the FDA DMF guidance。

SCOPE & APPROACH

What can this DMF service include?

Engage us for initial preparation, individual technical work or ongoing maintenance. Agree separately on studies, testing, translation and response rounds.

01

Type assessment and documentation gap list

Determine the type and scope based on the API, packaging or excipient use, the holder and the customer application. List available materials, missing studies and responsibilities.

02

Technical writing and document preparation

Write or organize agreed sections using the actual process, specifications, testing, stability and other applicable data. Check consistency across files and assess missing studies separately.

03

DMF number and eCTD submission support

Help with applicable pre-assigned numbers, administrative and signature documents, and electronic submission. Check versions, sequences and validation. Organize acknowledgements and follow-up after submission.

04

Letters of Authorization and customer coordination

Prepare or review the LOA, authorized parties and reference scope, and organize submission and handover records. Define holder, customer and service responsibilities for new or withdrawn authorizations.

If a customer has requested a reference, see the DMF LOA Guidefor responsibilities for issuing, submitting and handing over copies.

05

Technical amendments and annual maintenance

Prepare applicable amendments for technical, site or administrative changes. Prepare annual reports and authorization lists, and maintain version and submission histories. Address annual reporting and technical changes separately.

06

FDA responses and document handover

Review FDA administrative or technical questions, organize response materials and submissions, and handle holder, contact or agent changes and records handover within the agreed scope.

GET READY

What to prepare for scoping and a quote

Start with a nonconfidential summary. Share detailed confidential information after authorization, confidentiality and transfer arrangements are confirmed.

  • Material category and use, supported customer application and target DMF type
  • Basic holder, manufacturing facility and technical contact information
  • Initial filing or existing file, with DMF number and submission history if available
  • Inventory and gaps in process, quality controls, specifications, testing and stability records
  • Customer reference, LOA, amendments, annual reporting or FDA response needs
  • Expected scope, milestones, document language and coordination
HOW TO START

From documentation assessment through submission and ongoing maintenance

STEP 01

Confirm purpose and existing materials

Review material type, holder, customer reference plans and records to identify applicable work.

STEP 02

Agree on deliverables, timing and fees

Confirm gaps, sections, electronic submission, response and maintenance scope. Separate FDA, service and third-party fees.

STEP 03

Prepare documents and coordinate submission

Review and submit agreed materials, then record acknowledgements and feedback. Discuss missing documentation or added work as it arises.

STEP 04

Arrange references and lifecycle maintenance

Handle LOAs, amendments, annual reports and responses as needed. Hand over or maintain versions and submission records.

Services depend on accurate and complete technical and study data. Drug establishment registration, Drug Listing and marketing applications remain separate. Confirm studies, testing, full applications and other out-of-scope activities separately.

TIMING & FEES

Timing and fees

Information reviewed:Fee period: FY 2027, October 1, 2026 through September 30, 2027. For other charges, use the FDA rules as of the review date.

Timing and preparation

Document preparation

Initial writing depends on DMF type, completeness of technical materials and study gaps. Once documents are available, confirm sections, review rounds and the electronic submission plan. Agree on LOAs, annual reports or individual amendments by scope. Schedule additional research and testing separately.

FDA processing

A file number, submission acknowledgement, any applicable completeness assessment and technical review within a referencing application are separate stages. There is no uniform approval timeline for DMFs. Use acknowledgements and feedback to verify status.

Fee breakdown

FDA fees

The FY 2027 one-time GDUFA fee for applicable Type II API DMFs is US$109,899. It is triggered under applicable conditions such as the first reference or a request for an initial completeness assessment. Review Type III, Type IV and other uses separately. Establishment fees are separate where applicable.

Service fees

Quote initial writing or organization, eCTD publishing and submission, LOAs, individual amendments, annual maintenance and FDA responses by scope and term. Specify sections, products or materials, coordination and response rounds.

Other possible costs

Quote testing, additional research, translation, software and other third-party work separately. Applicable establishment fees and customer marketing application fees are separate.

OFFICIAL SOURCES

Official references for DMF technical files and electronic submissions

Reviewed November 6, 2026. Verify file type, technical requirements and referencing application arrangements against current FDA rules.

START WITH YOUR PRODUCT

Share your material and documentation status to confirm the DMF scope.

Provide file type, holder, customer reference plans and document inventory to discuss deliverables and pricing for initial writing, individual submissions or ongoing maintenance.